Stock Scorer

Korsana Biosciences, Inc. (CYCN)

Korsana Biosciences, Inc. reported revenue of 0 USD for the quarter ending 30 June 2026, down 100.0% from 93K a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 0 -100.0%
Operating Income Q2 '26 · ending 30 June 2026 -1.8M —
Net Income Q2 '26 · ending 30 June 2026 -1.8M —
Operating Cash Flow Q2 '26 · ending 30 June 2026 -1.4M —
Free Cash Flow Q2 '26 · ending 30 June 2026 -1.4M —
Shares Outstanding Q2 '26 · ending 30 June 2026 4.3M +66.3%
EPS Q2 '26 · ending 30 June 2026 -1.66 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 2.1M-5M-3.5M—
20242024-12-31 2M-3.6M-3.1M—
20232023-12-31 0-13M-5.3M—
20222022-12-31 297K-18.5M-44.1M-40.6M
20212021-12-31 3.9M-55.2M-51.6M-36.5M
20202020-12-31 2.3M-81.3M-77.8M-74M
20192019-12-31 4.5M-125M-123M-109.1M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-300
Q1 '262026-03-310
Q4 '252025-12-311M
Q3 '252025-09-30875K
Q2 '252025-06-3093K
Q1 '252025-03-3181K
Q4 '242024-12-311.8M
Q3 '242024-09-30194K
Q2 '242024-06-300
Q1 '242024-03-310
Q4 '232023-12-310
Q3 '232023-09-300
Q2 '232023-06-300
Q1 '232023-03-310
Q4 '222022-12-31-720K
Q3 '222022-09-300
Q2 '222022-06-30306K
Q1 '222022-03-31711K
Q4 '212021-12-31533K
Q3 '212021-09-30348K

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30-1.8M
Q1 '262026-03-31-3.2M
Q4 '252025-12-31-838K
Q3 '252025-09-30-1M
Q2 '252025-06-30-1.7M
Q1 '252025-03-31-1.5M
Q4 '242024-12-31502K
Q3 '242024-09-30-1.1M
Q2 '242024-06-30-1.4M
Q1 '242024-03-31-1.6M
Q4 '232023-12-31-1.8M
Q3 '232023-09-30-6M
Q2 '232023-06-30-1.9M
Q1 '232023-03-31-3.3M
Q4 '222022-12-3112.4M
Q3 '222022-09-30-4.5M
Q2 '222022-06-30-13.4M
Q1 '222022-03-31-13M
Q4 '212021-12-31-14.3M
Q3 '212021-09-30-11.3M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-30-1.8M
Q1 '262026-03-31-3.2M
Q4 '252025-12-31-799K
Q3 '252025-09-30-976K
Q2 '252025-06-30-324K
Q1 '252025-03-31-1.4M
Q4 '242024-12-31530K
Q3 '242024-09-30-723K
Q2 '242024-06-30-1.3M
Q1 '242024-03-31-1.5M
Q4 '232023-12-31-1.7M
Q3 '232023-09-307.6M
Q2 '232023-06-30-4.2M
Q1 '232023-03-31-7M
Q4 '222022-12-31-7.2M
Q3 '222022-09-30-10.5M
Q2 '222022-06-30-13.4M
Q1 '222022-03-31-13M
Q4 '212021-12-31-10.8M
Q3 '212021-09-30-11.3M

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30-1.4M
Q1 '262026-03-31-1.2M
Q4 '252025-12-31-1.6M
Q3 '252025-09-30-264K
Q2 '252025-06-30-503K
Q1 '252025-03-31-968K
Q4 '242024-12-31360K
Q3 '242024-09-30-1.7M
Q2 '242024-06-30-1.1M
Q1 '242024-03-31-1.9M
Q4 '232023-12-31-1.5M
Q3 '232023-09-30-6.9M
Q2 '232023-06-30-6.6M
Q1 '232023-03-31-6.2M
Q4 '222022-12-31-7M
Q3 '222022-09-30-9.9M
Q2 '222022-06-30-10.8M
Q1 '222022-03-31-12.8M
Q4 '212021-12-31-8.6M
Q3 '212021-09-30-7.9M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q2 '262026-06-30-1.4M
Q1 '262026-03-31-1.2M
Q2 '252025-06-30-503K
Q1 '252025-03-31-968K
Q4 '222022-12-31-7M
Q4 '212021-12-31-8.6M
Q4 '202020-12-31-14.1M
Q3 '202020-09-30-15.1M
Q2 '202020-06-30-14.3M
Q1 '202020-03-31-30.6M
Q4 '192019-12-31-22.3M
Q3 '192019-09-30-24.5M
Q2 '192019-06-30-26.2M
Q1 '192019-03-31-36.1M
Q4 '182018-12-31-25M
Q3 '182018-09-30-26.5M
Q2 '182018-06-30-22.9M
Q1 '182018-03-31-26.6M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-304.3M
Q1 '262026-03-314.2M
Q3 '252025-09-303.2M
Q2 '252025-06-303.1M
Q1 '252025-03-312.6M
Q3 '242024-09-302.5M
Q2 '242024-06-302.5M
Q1 '242024-03-312.5M
Q3 '232023-09-302.8M
Q2 '232023-06-302.3M
Q1 '232023-03-312.2M
Q3 '222022-09-302.2M
Q2 '222022-06-302.2M
Q1 '222022-03-3143.4K
Q3 '212021-09-3043.3M
Q2 '212021-06-3035.7M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q2 '262026-06-30-1.66
Q1 '262026-03-31-1.36
Q4 '252025-12-31-1.16
Q3 '252025-09-30-0.74
Q2 '252025-06-30-0.73
Q1 '252025-03-31-1.15
Q4 '242024-12-31-1.21
Q3 '242024-09-30-1.38
Q2 '242024-06-301.63
Q1 '242024-03-310.33
Q4 '232023-12-31-2.25
Q3 '232023-09-30-5.63
Q2 '232023-06-30-13.18
Q1 '232023-03-31-17.51
Q4 '212021-12-31-1.34
Q3 '212021-09-30-1.65
Q2 '212021-06-30-1.98
Q1 '212021-03-31-2.23
Q4 '202020-12-31-2.57
Q3 '202020-09-30-2.97